Technical Analysis for ABIO - ARCA biopharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
5.0752 | -1.45% | -0.07 |
ABIO closed down 1.45 percent on Thursday, November 14, 2019, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical ABIO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -1.45% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/13/2019
- Sector: Healthcare
- Industry: Biotechnology
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Broomfield, Colorado.
Biopharmaceutical Anatomy Cardiovascular Diseases Heart Failure Atrial Fibrillation Cardiac Arrhythmia Heart Diseases Ventricular Dysfunction
Biopharmaceutical Anatomy Cardiovascular Diseases Heart Failure Atrial Fibrillation Cardiac Arrhythmia Heart Diseases Ventricular Dysfunction
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ABIO news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 20.4499 |
| 52 Week Low | 4.68 |
| Average Volume | 87,866 |
| 200-Day Moving Average | 6.6805 |
| 50-Day Moving Average | 5.3851 |
| 20-Day Moving Average | 5.1973 |
| 10-Day Moving Average | 5.1315 |
| Average True Range | 0.3712 |
| ADX | 35.4 |
| +DI | 23.6937 |
| -DI | 8.6918 |
| Chandelier Exit (Long, 3 ATRs ) | 4.8864 |
| Chandelier Exit (Short, 3 ATRs ) | 6.0636 |
| Upper Bollinger Band | 5.4678 |
| Lower Bollinger Band | 4.9268 |
| Percent B (%b) | 0.27 |
| BandWidth | 10.409251 |
| MACD Line | -0.0687 |
| MACD Signal Line | -0.0757 |
| MACD Histogram | 0.007 |
| Fundamentals | Value |
|---|---|
| Market Cap | 59.61 Million |
| Num Shares | 11.7 Million |
| EPS | -2.05 |
| Price-to-Earnings (P/E) Ratio | -2.48 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.92 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.33 | ||||
| Resistance 3 (R3) | 5.34 | 5.27 | 5.29 | ||
| Resistance 2 (R2) | 5.27 | 5.21 | 5.26 | 5.27 | |
| Resistance 1 (R1) | 5.17 | 5.17 | 5.14 | 5.16 | 5.26 |
| Pivot Point | 5.10 | 5.10 | 5.08 | 5.10 | 5.10 |
| Support 1 (S1) | 5.00 | 5.04 | 4.97 | 4.99 | 4.89 |
| Support 2 (S2) | 4.93 | 5.00 | 4.93 | 4.88 | |
| Support 3 (S3) | 4.84 | 4.93 | 4.86 | ||
| Support 4 (S4) | 4.82 |
